Eikon Therapeutics(EIKN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

EIKN Eikon Therapeutics

盘前交易 10-23 05:31:30 EDT

8.24

+0.24

+3.00%

最高8.29	最低7.93	成交量34.86万
今开7.98	昨收8.00	日振幅4.56%
总市值4.45亿	流通市值1.45亿	总股本5,398万
成交额283.80万	换手率1.98%	流通股本1,765万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"EIKN","market":"US","secType":"STK","nameCN":"Eikon Therapeutics","latestPrice":8.24,"timestamp":1792699200000,"preClose":8,"halted":0,"volume":348580,"delay":0,"changeRate":0.030000000000000027,"floatShares":17648000,"shares":53984300,"eps":-5.95,"marketStatus":"盘前交易","change":0.24,"latestTime":"10-23 05:31:30 EDT","open":7.98,"high":8.29,"low":7.925,"amount":2837981.84758,"amplitude":0.045625,"askPrice":9.76,"askSize":100,"bidPrice":5.03,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-5.95,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792762200000},"marketStatusCode":1,"adr":0,"listingDate":1770267600000,"exchange":"NASDAQ","adjPreClose":8.24,"postHourTrading":{"tag":"盘后","latestPrice":8.24,"preClose":8.24,"latestTime":"19:47 EDT","volume":3183,"amount":26227.92,"timestamp":1792712871493,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7204304808767021},"requestUrl":"/m/hq/s/EIKN/tweets","defaultTab":"tweets","newsList":[{"id":"2658911994","title":"营收暴增无阻英派药业继续亏损：预计上半年减亏三成左右！股价早已破发","url":"https://stock-news.laohu8.com/highlight/detail?id=2658911994","media":"深圳商报·读创","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658911994?lang=zh_cn&edition=full","pubTime":"2026-08-11 23:03","pubTimestamp":1786460583,"startTime":"0","endTime":"0","summary":"8月11日，英派药业(07630.HK)发布盈利预告，公司预计2026年上半年收入约9470万元至1.16亿元，较去年同期约2520万元增长约276%至359%；预计期内亏损约8170万元至9990万元，较去年同期约1.29亿元减少约22%至37%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113838249182.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113838249182.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["EIKN","07630","BK4139","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143932807","title":"Eikon Therapeutics宣布晚期黑色素瘤Eik1001适应症2/3期试验Teluride-006进入剂量选择阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=1143932807","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143932807?lang=zh_cn&edition=full","pubTime":"2026-08-11 19:31","pubTimestamp":1786447878,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics今日对外披露，其针对晚期黑色素瘤开展的在研药物Eik1001，已正式进入一项名为Teluride-006的适应性2/3期临床试验的剂量选择阶段。这一里程碑标志着该研究方案向前迈出了关键一步。Eikon Therapeutics专注于开发创新疗法，以攻克难治性癌症。此次剂量选择的宣布，体现了公司对于严谨临床试验流程的坚守，以及对加速推进Eik1001临床开发进度的决心。市场分析人士正密切关注这一进展，因为若试验结果积极，Eik1001有望为晚期黑色素瘤患者群体带来新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181280733","title":"Eikon Therapeutics宣布Teluride-008临床试验首位患者给药，Eik1001用于非小细胞肺癌的注册性II/III期研究正式启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1181280733","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181280733?lang=zh_cn&edition=full","pubTime":"2026-07-27 19:32","pubTimestamp":1785151940,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics今日宣布，其在研药物Eik1001的注册性II/III期临床试验——Teluride-008，已完成首位患者给药。这项研究专注于非小细胞肺癌（NSCLC）的治疗。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116184350","title":"新闻稿：Eikon Therapeutics 宣布任命 Ma. Fatima D. Francisco 加入董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=1116184350","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116184350?lang=zh_cn&edition=full","pubTime":"2026-06-08 20:04","pubTimestamp":1780920252,"startTime":"0","endTime":"0","summary":"加州米尔布雷，2026年6月8日——致力于开发创新药物以解决严重未满足医疗需求的后期临床生物制药公司 Eikon Therapeutics, Inc.  今日宣布，任命 Ma. FatimaD. Francisco 女士为公司董事会独立董事，自2026年6月15日起生效。Francisco 女士还将担任董事会薪酬委员会成员。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eikontx.com","stockEarnings":[{"period":"1week","weight":0.0928},{"period":"1month","weight":-0.0824},{"period":"3month","weight":-0.0742},{"period":"6month","weight":-0.1466},{"period":"1year","weight":-0.5422},{"period":"ytd","weight":-0.5422}],"compareEarnings":[{"period":"1week","weight":-0.0101},{"period":"1month","weight":-0.0122},{"period":"3month","weight":0.0339},{"period":"6month","weight":0.0701},{"period":"1year","weight":0.144},{"period":"ytd","weight":0.1203}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Eikon Therapeutics, Inc.于2019年7月9日在特拉华州注册成立。该公司是一家后期临床生物制药公司，旨在开发创新药物，以解决重大未满足的医疗需求。该组织主要专注于肿瘤学，推进一系列候选药物，旨在满足大适应症内的高未满足需求。该领导班子有着成功研发有冲击力药物的显著历史。该公司的战略包括利用专有技术平台创造新疗法，其主要候选药物针对晚期黑色素瘤和非小细胞肺癌等严重疾病。","exchange":"NASDAQ","name":"Eikon Therapeutics","nameEN":"Eikon Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Eikon Therapeutics(EIKN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Eikon Therapeutics(EIKN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Eikon Therapeutics,EIKN,Eikon Therapeutics股票,Eikon Therapeutics股票老虎,Eikon Therapeutics股票老虎国际,Eikon Therapeutics行情,Eikon Therapeutics股票行情,Eikon Therapeutics股价,Eikon Therapeutics股市,Eikon Therapeutics股票价格,Eikon Therapeutics股票交易,Eikon Therapeutics股票购买,Eikon Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Eikon Therapeutics(EIKN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Eikon Therapeutics(EIKN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}